Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPD
Author(s)
Caramori, G
Chung, KF
Adcock, IM
Type
Journal Article
Date Issued
2014-01-24
Date Acceptance
2014-01-24
Citation
International Journal of Chronic Obstructive Pulmonary Disease, 2014, 9 (1), pp.249-256
ISSN
1176-9106
Publisher
Dove Medical Press
Start Page
249
End Page
256
Journal / Book Title
International Journal of Chronic Obstructive Pulmonary Disease
Volume
9
Issue
1
Copyright Statement
© 2014 Caramori et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/.
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/.
License URL
Sponsor
Wellcome Trust
Grant Number
093080/Z/10/Z
Subjects
Science & Technology
Life Sciences & Biomedicine
Respiratory System
COPD
LABA
ULABA
ICS
bronchodilator
new drugs
OBSTRUCTIVE PULMONARY-DISEASE
GLUCOCORTICOID-RECEPTOR
RANDOMIZED-TRIAL
VILANTEROL TRIFENATATE
MEDICATION ADHERENCE
BETA(2) AGONISTS
HEALTHY-SUBJECTS
LUNG-FUNCTION
IN-VITRO
MU-G
Administration, Inhalation
Adrenergic beta-2 Receptor Agonists
Androstadienes
Animals
Benzyl Alcohols
Bronchodilator Agents
Chlorobenzenes
Drug Combinations
Dry Powder Inhalers
Glucocorticoids
Humans
Powders
Pulmonary Disease, Chronic Obstructive
Treatment Outcome
1102 Cardiovascular Medicine And Haematology
Publication Status
Published